Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology

After over a decade extending the half-life of medicines for J&J, Genentech and other large players, Amunix is pivoting to develop elements of its platform into off-the-shelf CAR–T treatments and other immun-oncology treatments. And they’re licensing a portion of the older technology to Roche for $40 million and $1.5 billion in potential milestones.